SCHEMBL299247

SCHEMBL299247

N#CNS(=O)(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
KEAP1 Q14145 3/20 0.50
IL1RN P18510 1/20 0.50
ERAP1 Q9NZ08 1/20 0.50
ALDH1A1 P00352 3/20 0.47
PKM P14618 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
IDO1 P14902 1/20 0.44
HTR6 P50406 1/20 0.44
CTSB P07858 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210772 0.79 CA1 (0.54) CA1CA2MMP1MMP2MMP9
SCHEMBL25340319 0.78 IDO1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL7364561 0.78 GAA (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL8645355 0.78 CA1 (0.55) CA1CA2MMP1MMP2MMP9
SCHEMBL2468179 0.77 MMP2 (0.52) CA1CA2MMP1MMP2MMP9
SCHEMBL4911074 0.77 CA1 (0.52) CA1CA2MMP1MMP2MMP9
SCHEMBL3246013 0.77 CA2 (0.52) CA1CA2MMP1MMP2MMP9
SCHEMBL9414303 0.77 KMT2A (0.35) CA1CA2MMP1MMP2MMP9
SCHEMBL9414304 0.77 POLB (0.56) CA1CA2ALDH1A1PKMKMT2A
SCHEMBL10529505 0.73 CA1 (0.58) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2023-03-16 US disclosed
WO-2020211836-A1 BENZENE PIPERIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF 北京酷瓴生物技术有限公司 2020-10-22 WO disclosed
CN-110218172-A A method of N- aryl sulfonic acid amides are prepared by indoline and aryl sulfonic acid amides 常州大学 2019-09-10 CN disclosed
CN-109966294-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维爱尔兰无限公司 2019-07-05 CN disclosed
CN-109897038-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维爱尔兰无限公司 2019-06-18 CN disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 US disclosed
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 US disclosed
CN-108473424-A Compound, light-emitting material, and organic light-emitting element 九州有机光材股份有限公司 2018-08-31 CN disclosed
CN-108175749-A The solid dispersions of melt extrusion containing cell death inducer 艾伯维爱尔兰无限公司 2018-06-19 CN disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 US disclosed
EP-0906310-A4 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 1999-09-01 EP disclosed
EP-0906310-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1999-04-07 EP disclosed
WO-1997046556-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1997-12-11 WO disclosed
EP-0124479-B1 IMINOSULFON AMIDES AND PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS, AND THE COMPOUNDS FOR USE CIBA-GEIGY AG (CH) 1988-01-20 EP disclosed
US-4591597-A FOR BLOOD SUGAR REDUCTION CIBA-GEIGY CORPORATION (US) 1986-05-27 US disclosed
EP-0124479-A1 Iminosulfon amides and processes for their preparation, pharmaceutical preparations containing such compounds, and the compounds for use CIBA-GEIGY AG (CH) 1984-11-07 EP disclosed
US-4150051-A N-Cyanosulfonamide compounds CIBA-GEIGY CORPORATION (US) 1979-04-17 US disclosed
US-4075185-A ADDITION POLYMERIZATION CIBA-GEIGY CORPORATION (US) 1978-02-21 US disclosed
US-3997603-A Herbicidal halo-di-alkyl benzenesulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-12-14 US disclosed
US-3997603-A Herbicidal halo-di-alkyl benzenesulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 CA1 1327/4885CA2 766/4885MMP1 3483/4885
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 CA1 1741/4885CA2 1885/4885MMP1 3068/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 CA1 1327/4885CA2 766/4885MMP1 3483/4885
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 CA1 1741/4885CA2 1885/4885MMP1 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.